DR. STEPHEN G. ODAIBO
CEO & Founder
Dr. Stephen G. Odaibo is a Retina specialist, Mathematician, Computer Scientist, and Full-Stack Ai Engineer. He is the first Ophthalmologist in the world to ever hold advanced degrees in both Mathematics and Computer Science. In 2017 UAB College of Arts & Sciences awarded Dr. Odaibo its highest honor: The Distinguished Alumni Achievement Award. In 2005 he won the Barrie Hurwitz Award for Excellence in Clinical Neurology at Duke Univ. School of Medicine where he topped the class in Neurology and in Pediatrics. Dr. Odaibo Chaired the 2019 "Artificial Intelligence & Tech in Medicine" Symposium at the NMA. He is author of the book ``Quantum Mechanics and the MRI Machine'' (2012), and of the book "The Form of Finite Groups: A Course on Finite Group Theory" (2016).
Dr. Odaibo is a Faculty member at MD Anderson Cancer Center, the world's #1 cancer treatment center. He is on the inaugural Faculty of the Stanford Retina Innovation Summit; and he is a Faculty member at the University of Houston School of Medicine.
Dr. Odaibo obtained a B.S. in Math (UAB, 2001), M.S. in Math (UAB, 2002), M.S. in Computer Science (Duke, 2009), and Doctor of Medicine--MD (Duke, 2010). From 2004 to 2006, Dr. Odaibo was in the lab studying GPCRs with Dr. Robert J. Lefkowitz, the 2012 Nobel Laureate in Chemistry. Dr. Odaibo completed his Internship in Internal Medicine at Duke Univ. Hospital in 2011, his Residency in Ophthalmology at Howard Univ. Hospital in 2014, and his Fellowship in Medical Retina at the Univ. of Michigan in 2015.
In Oct 2011 Dr. Odaibo's cornea paper was chosen by MIT Technology Review as one of the best papers from Physics or Computer science submitted to the arXiv. In that paper, he provided the first quantitative demonstration of non-paraxial light bending in the human cornea. In 2020, Dr. Odaibo conjectured and proved the Hamiltonian Maximality Theorem.
Clinically, Dr. Odaibo focuses on caring for patients with macular degeneration, diabetic retinopathy, retinal vascular occlusions, retinal tears, and localized retinal detachments. He loves caring for patients and consistently receives excellent reviews from his patients (5.0/5.0 on Healthgrades).
As a CEO, Dr. Odaibo's uniquely multi-disciplinary background enables him to be actively involved in all aspects of the company's operations. He led the company's Series A financing campaign which raised $5.2M during a record 6 weeks from start to finish.